These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35411762)

  • 1. Investigation of the relationship between serum sclerostin and dickkopf-1 protein levels with bone turnover in children and adolescents with type-1 diabetes mellitus.
    Kurban S; Selver Eklioglu B; Selver MB
    J Pediatr Endocrinol Metab; 2022 May; 35(5):673-679. PubMed ID: 35411762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Sclerostin and Dickkopf-1 (DKK-1) Serum Levels in Children and Adolescents With Type 1 Diabetes Mellitus.
    Faienza MF; Ventura A; Delvecchio M; Fusillo A; Piacente L; Aceto G; Colaianni G; Colucci S; Cavallo L; Grano M; Brunetti G
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1174-1181. PubMed ID: 28388723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
    Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
    J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density.
    Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
    Pediatr Diabetes; 2016 Jun; 17(4):289-99. PubMed ID: 26094958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
    Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
    Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin and Dickkopf-1 in renal osteodystrophy.
    Cejka D; Herberth J; Branscum AJ; Fardo DW; Monier-Faugere MC; Diarra D; Haas M; Malluche HH
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):877-82. PubMed ID: 21164019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
    Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
    Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
    Peng J; Dong Z; Hui Z; Aifei W; Lianfu D; Youjia X
    BMC Musculoskelet Disord; 2021 May; 22(1):480. PubMed ID: 34034718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
    Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
    BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL.
    Niu CC; Lin SS; Yuan LJ; Chen LH; Yang CY; Chung AN; Lu ML; Tsai TT; Lai PL; Chen WJ
    BMC Musculoskelet Disord; 2017 Feb; 18(1):61. PubMed ID: 28153008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased Serum Wnt Antagonist Levels in Patients With Active Acromegaly.
    Chen H; Huang H; Wang Y; Zhang Y; Liu M; Lou Y; Zhang Z; Zhu D; Li P
    Endocr Pract; 2022 May; 28(5):515-520. PubMed ID: 35123069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.
    Ivanova MM; Dao J; Kasaci N; Friedman A; Noll L; Goker-Alpan O
    Front Endocrinol (Lausanne); 2022; 13():1029130. PubMed ID: 36506070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes.
    Fazeli PK; Ackerman KE; Pierce L; Guereca G; Bouxsein M; Misra M
    Osteoporos Int; 2013 Sep; 24(9):2433-40. PubMed ID: 23579340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.